Bill Sibold serves as the President and Chief Executive Officer at Madrigal Pharmaceuticals, Inc., a position he has held since joining the company. With a robust background in the biopharmaceutical industry, Sibold brings extensive experience in leading and growing organizations focused on developing innovative therapies. Prior to his role at Madrigal, he held significant leadership positions at major pharmaceutical companies, where he was instrumental in driving strategic initiatives and overseeing the successful development and commercialization of new drugs. At Madrigal Pharmaceuticals, Sibold has been pivotal in steering the company's mission to address unmet medical needs in liver and cardiovascular diseases. Under his leadership, the company has advanced its lead candidate, resmetirom, through various stages of clinical trials, aiming to provide a novel treatment for non-alcoholic steatohepatitis (NASH). His strategic vision and operational expertise have been crucial in positioning Madrigal as a key player in the biopharmaceutical sector, fostering a culture of innovation and excellence within the organization. Sibold's achievements extend beyond his current role, as he has a track record of successfully navigating complex regulatory environments and building high-performing teams. His commitment to advancing patient care is evident in his dedication to the development of transformative therapies. As CEO, he continues to guide Madrigal Pharmaceuticals towards its goal of bringing new, effective treatments to market, thereby making a significant impact on the lives of patients worldwide.